Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Inventiva S.A. ADR
(NQ:
IVA
)
2.400
+0.020 (+0.84%)
Streaming Delayed Price
Updated: 3:53 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Inventiva S.A. ADR
< Previous
1
2
3
4
Next >
Inventiva's NASH Pact In China Represents 'Financially Prudent Pathway,' Says This Analyst
September 26, 2022
Via
Benzinga
Week In Review: Sino Biopharma Subsidiary Enters $307 Million Agreement For Rights To NASH Candidate
September 24, 2022
Chia Tai-Tianqing Pharma, a subsidiary of Sino Biopharma, in-licensed Greater China rights to a therapy for non-alcoholic steatohepatitis from Inventiva in a $307 million deal. Meanwhile, CASI Pharma...
Via
Talk Markets
Dow Turns Higher; Crude Oil Rises 0.7%
September 22, 2022
U.S. stocks pared some losses, with the Dow Jones turning higher toward the end of trading on Thursday.
Via
Benzinga
Nasdaq Drops Over 100 Points; Spero Therapeutics Shares Spike Higher
September 22, 2022
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping more than 100 points on Thursday.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
September 22, 2022
Gainers Spero Therapeutics (NASDAQ:SPRO) shares moved upwards by 122.7% to $1.83 during Thursday's pre-market session. The market value of their outstanding shares is at $64.1 million.
Via
Benzinga
Inventiva Inks Licensing Pact With China-Based Sino Biopharm For NASH Candidate In Greater China
September 22, 2022
Via
Benzinga
Inventiva Raises €50M Debt Financing To Fund Its Lead Program In NASH Patients
May 16, 2022
Via
Benzinga
Why MediWound Is Trading Lower By Around 18%, Here Are 48 Stocks Moving In Thursday's Mid-Day Session
September 22, 2022
Gainers
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
September 21, 2022
Gainers Pulmatrix (NASDAQ:PULM) shares rose 11.9% to $4.3 during Wednesday's after-market session. The company's market cap stands at $14.5 million.
Via
Benzinga
Earnings Scheduled For September 21, 2022
September 21, 2022
Companies Reporting Before The Bell • General Mills (NYSE:GIS) is projected to report quarterly earnings at $1.00 per share on revenue of $4.72 billion.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
August 02, 2022
Tuesday's session saw 63 companies set new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
July 21, 2022
During Thursday's trading, 50 companies set new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
July 19, 2022
Tuesday saw 37 companies set new 52-week lows.
Via
Benzinga
51 Biggest Movers From Yesterday
April 07, 2022
Gainers Advent Technologies Holdings, Inc. (NASDAQ: ADN) shares climbed 79.7% to close at $3.63 on Wednesday. Advent Technologies and Hyundai Motor Company entered into...
Via
Benzinga
40 Stocks Moving In Wednesday's Mid-Day Session
April 06, 2022
Gainers Advent Technologies Holdings, Inc. (NASDAQ: ADN) shares jumped 77.7% to $3.5950. Advent Technologies and Hyundai Motor Company entered into technology assessment, sales...
Via
Benzinga
21 Stocks Moving in Wednesday's Pre-Market Session
April 06, 2022
Gainers Dakota Gold (NYSE: DC) shares rose 97.1% to $13.60 in pre-market trading. The company’s stock was uplisted to NYSE American on Tuesday. BigBear.ai Holdings,...
Via
Benzinga
The Daily Biotech Pulse: Moderna Outlines Steps For mRNA Tech Advancement, Voyager-Novartis Strike Licensing Deal, Valneva Reports Positive Chikungunya Shot Readout
March 08, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Moderna Announces 4 Initiatives To Advance mRNA Vaccines As Preventative...
Via
Benzinga
FDA Gives Green Signal To Inventiva's Mid-Stage Lanifibranor Study In NASH Patients
March 08, 2022
The FDA has completed a safety review of Inventiva SA's (NASDAQ: IVA) IND application and signed off Phase 2 combination trial with its lead drug candidate...
Via
Benzinga
Earnings Scheduled For March 7, 2022
March 07, 2022
Companies Reporting Before The Bell • Niu Technologies (NASDAQ:NIU) is expected to report quarterly earnings at $0.21 per share on revenue of $144.02 million. •...
Via
Benzinga
The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program
February 01, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Inventiva Posts Results of Clinical Thorough QT Study Of Lanifibranor
December 07, 2021
Inventiva (NASDAQ: IVA) announced the results of a clinical thorough QT/QTc study demonstrating the safety of lanifibranor on cardiac electrical activity. The...
Via
Benzinga
Inventiva Plans To Start Lanifibranor Combo Study In NASH, Diabetes In 2022
October 28, 2021
Inventiva (NASDAQ: IVA) announced the design of Phase 2a combination trial of lanifibranor in patients with type 2 diabetes (T2D) and non-cirrhotic non-alcoholic...
Via
Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
September 22, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (...
Via
Benzinga
Fast Track Status Expanded For Inventiva's NASH Treatment
September 22, 2021
The FDA has decided that the Fast Track designation previously granted to Inventiva SA's (NASDAQ: IVA) lanifibranor in NASH encompasses the treatment of NASH...
Via
Benzinga
Exposures
Product Safety
Earnings Scheduled For September 20, 2021
September 20, 2021
Companies Reporting Before The Bell • Cognyte Software (NASDAQ:CGNT) is expected to report quarterly earnings at $0.15 per share on revenue of $115.57 million. ...
Via
Benzinga
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
September 09, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:...
Via
Benzinga
Exposures
COVID-19
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
August 12, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
August 10, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (...
Via
Benzinga
Exposures
COVID-19
12 Health Care Stocks Moving In Thursday's Pre-Market Session
August 05, 2021
Gainers Ensysce Biosciences (NASDAQ:ENSC) shares rose 42.78% to $5.84 during Thursday's pre-market session. The company's market cap stands at $141.7 million....
Via
Benzinga
The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs
June 25, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24) AngioDynamics, Inc. (NASDAQ...
Via
Benzinga
Exposures
COVID-19
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.